Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
Identifieur interne : 000225 ( Main/Exploration ); précédent : 000224; suivant : 000226Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
Auteurs : Jan Donck [Belgique] ; Lourdes Gonzalez-Tabares [Espagne] ; Jacques Chanliau [France] ; Heike Martin [Allemagne] ; Kyriaki Stamatelou [Grèce] ; Nick Manamley [Royaume-Uni] ; Mourad Farouk [Suisse] ; Janet Addison [Royaume-Uni]Source :
- Advances in Therapy [ 0741-238X ] ; 2014.
Abstract
There is scant real-world information on switching treatment for anemia associated with chronic kidney disease (CKD) from methoxy polyethylene glycol-epoetin beta (PEG-Epo) to darbepoetin alfa (DA). TRANSFORM was a multi-center, observational study designed to describe the time course of hemoglobin (Hb) concentration (primary outcome measure) and other parameters of clinical management of anemia in European hemodialysis patients in clinical practice before and after a switch from PEG-Epo to DA.
Eligible subjects were adult patients with CKD dialyzed at European dialysis centers for ≥26 weeks and treated with PEG-Epo for ≥14 weeks immediately prior to being switched to DA and no earlier than January 2011. Erythropoiesis-stimulating agent doses and Hb values were recorded for the 14-week pre-switch and 26-week post-switch periods.
Of the 1,027 eligible patients enrolled at 42 hemodialysis centers in 7 European countries, 785 were included in analyses. Mean (95% confidence interval [CI]) Hb was generally stable: 11.19 (11.11, 11.26), 11.48 (11.40, 11.57), and 11.29 (11.20, 11.37) g/dL at month −1 pre-switch and months 3 and 6 post-switch, respectively. The geometric mean (95% CI) PEG-Epo dose at month −1 was 27.4 (26.0, 28.8) µg/week; DA dose was 29.4 (27.9, 30.9), 23.3 (21.9, 24.9), and 25.6 (24.1, 27.1) µg/week at months 1, 4, and 6, respectively. The geometric mean (95% CI) dose ratio at switching was 1.06 (1.01, 1.11). When stratifying by dose-ratio categories <0.8, 0.8–1.2, and >1.2 at switching, mean DA dose and Hb converged within narrow ranges by month 6 post-switch: 23.9–27.0 µg/week and 11.1–11.5 g/dL, respectively. Hb excursions <10 g/dL were less frequent post-switch versus pre-switch.
Mean Hb values remained within a narrow range following switching from PEG-Epo to DA in this population of hemodialysis patients. Time trends of mean Hb and DA dose indicate that physicians titrated DA doses post-switch, to attain Hb concentrations comparable to those attained pre-switch with PEG-Epo.
Amgen (Europe) GmbH, Zug, Switzerland.
The online version of this article (doi:10.1007/s12325-014-0161-5) contains supplementary material, which is available to authorized users.
Url:
DOI: 10.1007/s12325-014-0161-5
PubMed: 25367412
PubMed Central: 4245491
Affiliations:
- Allemagne, Belgique, Espagne, France, Grèce, Royaume-Uni, Suisse
- Province de Flandre-Orientale
- Gand, Nancy, Vandœuvre-lès-Nancy
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000132
- to stream Pmc, to step Curation: 000132
- to stream Pmc, to step Checkpoint: 000190
- to stream Ncbi, to step Merge: 000268
- to stream Ncbi, to step Curation: 000268
- to stream Ncbi, to step Checkpoint: 000268
- to stream Main, to step Merge: 000225
- to stream Main, to step Curation: 000225
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study</title><author><name sortKey="Donck, Jan" sort="Donck, Jan" uniqKey="Donck J" first="Jan" last="Donck">Jan Donck</name><affiliation wicri:level="3"><nlm:aff id="Aff1">Algemeen Ziekenhuis Sint Lucas, Groenebriel 1, 9000 Ghent, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Algemeen Ziekenhuis Sint Lucas, Groenebriel 1, 9000 Ghent</wicri:regionArea><placeName><region type="province" nuts="2">Province de Flandre-Orientale</region><settlement type="city">Gand</settlement></placeName></affiliation></author><author><name sortKey="Gonzalez Tabares, Lourdes" sort="Gonzalez Tabares, Lourdes" uniqKey="Gonzalez Tabares L" first="Lourdes" last="Gonzalez-Tabares">Lourdes Gonzalez-Tabares</name><affiliation wicri:level="1"><nlm:aff id="Aff2">Hospital Policlinico La Rosaleda, Santiago de Compostela, Spain</nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Policlinico La Rosaleda, Santiago de Compostela</wicri:regionArea><wicri:noRegion>Santiago de Compostela</wicri:noRegion></affiliation></author><author><name sortKey="Chanliau, Jacques" sort="Chanliau, Jacques" uniqKey="Chanliau J" first="Jacques" last="Chanliau">Jacques Chanliau</name><affiliation wicri:level="1"><nlm:aff id="Aff3">Association Lorraine pour le Traitement de l’Insuffisance Rénale (ALTIR), Vandoeuvre-lès-Nancy, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Association Lorraine pour le Traitement de l’Insuffisance Rénale (ALTIR), Vandoeuvre-lès-Nancy</wicri:regionArea><placeName><settlement type="city">Vandœuvre-lès-Nancy</settlement><settlement type="city" wicri:auto="agglo">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Martin, Heike" sort="Martin, Heike" uniqKey="Martin H" first="Heike" last="Martin">Heike Martin</name><affiliation wicri:level="1"><nlm:aff id="Aff4">Dialysezentrum Zwickau, Zwickau, Germany</nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea>Dialysezentrum Zwickau, Zwickau</wicri:regionArea><wicri:noRegion>Zwickau</wicri:noRegion><wicri:noRegion>Zwickau</wicri:noRegion><wicri:noRegion>Zwickau</wicri:noRegion></affiliation></author><author><name sortKey="Stamatelou, Kyriaki" sort="Stamatelou, Kyriaki" uniqKey="Stamatelou K" first="Kyriaki" last="Stamatelou">Kyriaki Stamatelou</name><affiliation wicri:level="1"><nlm:aff id="Aff5">“Kyanous Stavros” Hospital, Athens, Greece</nlm:aff><country xml:lang="fr">Grèce</country><wicri:regionArea>“Kyanous Stavros” Hospital, Athens</wicri:regionArea><wicri:noRegion>Athens</wicri:noRegion></affiliation></author><author><name sortKey="Manamley, Nick" sort="Manamley, Nick" uniqKey="Manamley N" first="Nick" last="Manamley">Nick Manamley</name><affiliation wicri:level="1"><nlm:aff id="Aff6">Amgen (UK) Limited, Cambridge, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Amgen (UK) Limited, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Farouk, Mourad" sort="Farouk, Mourad" uniqKey="Farouk M" first="Mourad" last="Farouk">Mourad Farouk</name><affiliation wicri:level="1"><nlm:aff id="Aff7">Amgen (Europe) GmbH, Zug, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Amgen (Europe) GmbH, Zug</wicri:regionArea><wicri:noRegion>Zug</wicri:noRegion></affiliation></author><author><name sortKey="Addison, Janet" sort="Addison, Janet" uniqKey="Addison J" first="Janet" last="Addison">Janet Addison</name><affiliation wicri:level="1"><nlm:aff id="Aff6">Amgen (UK) Limited, Cambridge, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Amgen (UK) Limited, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25367412</idno><idno type="pmc">4245491</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245491</idno><idno type="RBID">PMC:4245491</idno><idno type="doi">10.1007/s12325-014-0161-5</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000132</idno><idno type="wicri:Area/Pmc/Curation">000132</idno><idno type="wicri:Area/Pmc/Checkpoint">000190</idno><idno type="wicri:Area/Ncbi/Merge">000268</idno><idno type="wicri:Area/Ncbi/Curation">000268</idno><idno type="wicri:Area/Ncbi/Checkpoint">000268</idno><idno type="wicri:doubleKey">0741-238X:2014:Donck J:preservation:of:anemia</idno><idno type="wicri:Area/Main/Merge">000225</idno><idno type="wicri:Area/Main/Curation">000225</idno><idno type="wicri:Area/Main/Exploration">000225</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study</title><author><name sortKey="Donck, Jan" sort="Donck, Jan" uniqKey="Donck J" first="Jan" last="Donck">Jan Donck</name><affiliation wicri:level="3"><nlm:aff id="Aff1">Algemeen Ziekenhuis Sint Lucas, Groenebriel 1, 9000 Ghent, Belgium</nlm:aff><country xml:lang="fr">Belgique</country><wicri:regionArea>Algemeen Ziekenhuis Sint Lucas, Groenebriel 1, 9000 Ghent</wicri:regionArea><placeName><region type="province" nuts="2">Province de Flandre-Orientale</region><settlement type="city">Gand</settlement></placeName></affiliation></author><author><name sortKey="Gonzalez Tabares, Lourdes" sort="Gonzalez Tabares, Lourdes" uniqKey="Gonzalez Tabares L" first="Lourdes" last="Gonzalez-Tabares">Lourdes Gonzalez-Tabares</name><affiliation wicri:level="1"><nlm:aff id="Aff2">Hospital Policlinico La Rosaleda, Santiago de Compostela, Spain</nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Policlinico La Rosaleda, Santiago de Compostela</wicri:regionArea><wicri:noRegion>Santiago de Compostela</wicri:noRegion></affiliation></author><author><name sortKey="Chanliau, Jacques" sort="Chanliau, Jacques" uniqKey="Chanliau J" first="Jacques" last="Chanliau">Jacques Chanliau</name><affiliation wicri:level="1"><nlm:aff id="Aff3">Association Lorraine pour le Traitement de l’Insuffisance Rénale (ALTIR), Vandoeuvre-lès-Nancy, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Association Lorraine pour le Traitement de l’Insuffisance Rénale (ALTIR), Vandoeuvre-lès-Nancy</wicri:regionArea><placeName><settlement type="city">Vandœuvre-lès-Nancy</settlement><settlement type="city" wicri:auto="agglo">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Martin, Heike" sort="Martin, Heike" uniqKey="Martin H" first="Heike" last="Martin">Heike Martin</name><affiliation wicri:level="1"><nlm:aff id="Aff4">Dialysezentrum Zwickau, Zwickau, Germany</nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea>Dialysezentrum Zwickau, Zwickau</wicri:regionArea><wicri:noRegion>Zwickau</wicri:noRegion><wicri:noRegion>Zwickau</wicri:noRegion><wicri:noRegion>Zwickau</wicri:noRegion></affiliation></author><author><name sortKey="Stamatelou, Kyriaki" sort="Stamatelou, Kyriaki" uniqKey="Stamatelou K" first="Kyriaki" last="Stamatelou">Kyriaki Stamatelou</name><affiliation wicri:level="1"><nlm:aff id="Aff5">“Kyanous Stavros” Hospital, Athens, Greece</nlm:aff><country xml:lang="fr">Grèce</country><wicri:regionArea>“Kyanous Stavros” Hospital, Athens</wicri:regionArea><wicri:noRegion>Athens</wicri:noRegion></affiliation></author><author><name sortKey="Manamley, Nick" sort="Manamley, Nick" uniqKey="Manamley N" first="Nick" last="Manamley">Nick Manamley</name><affiliation wicri:level="1"><nlm:aff id="Aff6">Amgen (UK) Limited, Cambridge, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Amgen (UK) Limited, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Farouk, Mourad" sort="Farouk, Mourad" uniqKey="Farouk M" first="Mourad" last="Farouk">Mourad Farouk</name><affiliation wicri:level="1"><nlm:aff id="Aff7">Amgen (Europe) GmbH, Zug, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Amgen (Europe) GmbH, Zug</wicri:regionArea><wicri:noRegion>Zug</wicri:noRegion></affiliation></author><author><name sortKey="Addison, Janet" sort="Addison, Janet" uniqKey="Addison J" first="Janet" last="Addison">Janet Addison</name><affiliation wicri:level="1"><nlm:aff id="Aff6">Amgen (UK) Limited, Cambridge, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Amgen (UK) Limited, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author></analytic><series><title level="j">Advances in Therapy</title><idno type="ISSN">0741-238X</idno><idno type="eISSN">1865-8652</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Introduction</title><p>There is scant real-world information on switching treatment for anemia associated with chronic kidney disease (CKD) from methoxy polyethylene glycol-epoetin beta (PEG-Epo) to darbepoetin alfa (DA). TRANSFORM was a multi-center, observational study designed to describe the time course of hemoglobin (Hb) concentration (primary outcome measure) and other parameters of clinical management of anemia in European hemodialysis patients in clinical practice before and after a switch from PEG-Epo to DA.</p></sec><sec><title>Methods</title><p>Eligible subjects were adult patients with CKD dialyzed at European dialysis centers for ≥26 weeks and treated with PEG-Epo for ≥14 weeks immediately prior to being switched to DA and no earlier than January 2011. Erythropoiesis-stimulating agent doses and Hb values were recorded for the 14-week pre-switch and 26-week post-switch periods.</p></sec><sec><title>Results</title><p>Of the 1,027 eligible patients enrolled at 42 hemodialysis centers in 7 European countries, 785 were included in analyses. Mean (95% confidence interval [CI]) Hb was generally stable: 11.19 (11.11, 11.26), 11.48 (11.40, 11.57), and 11.29 (11.20, 11.37) g/dL at month −1 pre-switch and months 3 and 6 post-switch, respectively. The geometric mean (95% CI) PEG-Epo dose at month −1 was 27.4 (26.0, 28.8) µg/week; DA dose was 29.4 (27.9, 30.9), 23.3 (21.9, 24.9), and 25.6 (24.1, 27.1) µg/week at months 1, 4, and 6, respectively. The geometric mean (95% CI) dose ratio at switching was 1.06 (1.01, 1.11). When stratifying by dose-ratio categories <0.8, 0.8–1.2, and >1.2 at switching, mean DA dose and Hb converged within narrow ranges by month 6 post-switch: 23.9–27.0 µg/week and 11.1–11.5 g/dL, respectively. Hb excursions <10 g/dL were less frequent post-switch versus pre-switch.</p></sec><sec><title>Conclusion</title><p>Mean Hb values remained within a narrow range following switching from PEG-Epo to DA in this population of hemodialysis patients. Time trends of mean Hb and DA dose indicate that physicians titrated DA doses post-switch, to attain Hb concentrations comparable to those attained pre-switch with PEG-Epo.</p></sec><sec><title>Funding</title><p>Amgen (Europe) GmbH, Zug, Switzerland.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s12325-014-0161-5) contains supplementary material, which is available to authorized users.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Stauffer, Me" uniqKey="Stauffer M">ME Stauffer</name></author><author><name sortKey="Fan, T" uniqKey="Fan T">T Fan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Astor, Bc" uniqKey="Astor B">BC Astor</name></author><author><name sortKey="Muntner, P" uniqKey="Muntner P">P Muntner</name></author><author><name sortKey="Levin, A" uniqKey="Levin A">A Levin</name></author><author><name sortKey="Eustace, Ja" uniqKey="Eustace J">JA Eustace</name></author><author><name sortKey="Coresh, J" uniqKey="Coresh J">J Coresh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kazmi, Wh" uniqKey="Kazmi W">WH Kazmi</name></author><author><name sortKey="Kausz, At" uniqKey="Kausz A">AT Kausz</name></author><author><name sortKey="Khan, S" uniqKey="Khan S">S Khan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eschbach, Jw" uniqKey="Eschbach J">JW Eschbach</name></author><author><name sortKey="Adamson, Jw" uniqKey="Adamson J">JW Adamson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Horl, Wh" uniqKey="Horl W">WH Hörl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eckardt, Ku" uniqKey="Eckardt K">KU Eckardt</name></author><author><name sortKey="Kim, J" uniqKey="Kim J">J Kim</name></author><author><name sortKey="Kronenberg, F" uniqKey="Kronenberg F">F Kronenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gilbertson, Dt" uniqKey="Gilbertson D">DT Gilbertson</name></author><author><name sortKey="Ebben, Jp" uniqKey="Ebben J">JP Ebben</name></author><author><name sortKey="Foley, Rn" uniqKey="Foley R">RN Foley</name></author><author><name sortKey="Weinhandl, Ed" uniqKey="Weinhandl E">ED Weinhandl</name></author><author><name sortKey="Bradbury, Bd" uniqKey="Bradbury B">BD Bradbury</name></author><author><name sortKey="Collins, Aj" uniqKey="Collins A">AJ Collins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Macdougall, Ic" uniqKey="Macdougall I">IC Macdougall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Horl, Wh" uniqKey="Horl W">WH Hörl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burnier, M" uniqKey="Burnier M">M Burnier</name></author><author><name sortKey="Douchamps, Ja" uniqKey="Douchamps J">JA Douchamps</name></author><author><name sortKey="Tanghe, A" uniqKey="Tanghe A">A Tanghe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Macdougall, Ic" uniqKey="Macdougall I">IC Macdougall</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Carrera, F" uniqKey="Carrera F">F Carrera</name></author><author><name sortKey="Lok, Ce" uniqKey="Lok C">CE Lok</name></author><author><name sortKey="De Francisco, A" uniqKey="De Francisco A">A de Francisco</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Canaud, B" uniqKey="Canaud B">B Canaud</name></author><author><name sortKey="Mingardi, G" uniqKey="Mingardi G">G Mingardi</name></author><author><name sortKey="Braun, J" uniqKey="Braun J">J Braun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Choi, P" uniqKey="Choi P">P Choi</name></author><author><name sortKey="Farouk, M" uniqKey="Farouk M">M Farouk</name></author><author><name sortKey="Manamley, N" uniqKey="Manamley N">N Manamley</name></author><author><name sortKey="Addison, J" uniqKey="Addison J">J Addison</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meier, P" uniqKey="Meier P">P Meier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Locatelli, F" uniqKey="Locatelli F">F Locatelli</name></author><author><name sortKey="Barany, P" uniqKey="Barany P">P Bárány</name></author><author><name sortKey="Covic, A" uniqKey="Covic A">A Covic</name></author></analytic></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Allemagne</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Grèce</li><li>Royaume-Uni</li><li>Suisse</li></country><region><li>Province de Flandre-Orientale</li></region><settlement><li>Gand</li><li>Nancy</li><li>Vandœuvre-lès-Nancy</li></settlement></list><tree><country name="Belgique"><region name="Province de Flandre-Orientale"><name sortKey="Donck, Jan" sort="Donck, Jan" uniqKey="Donck J" first="Jan" last="Donck">Jan Donck</name></region></country><country name="Espagne"><noRegion><name sortKey="Gonzalez Tabares, Lourdes" sort="Gonzalez Tabares, Lourdes" uniqKey="Gonzalez Tabares L" first="Lourdes" last="Gonzalez-Tabares">Lourdes Gonzalez-Tabares</name></noRegion></country><country name="France"><noRegion><name sortKey="Chanliau, Jacques" sort="Chanliau, Jacques" uniqKey="Chanliau J" first="Jacques" last="Chanliau">Jacques Chanliau</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Martin, Heike" sort="Martin, Heike" uniqKey="Martin H" first="Heike" last="Martin">Heike Martin</name></noRegion></country><country name="Grèce"><noRegion><name sortKey="Stamatelou, Kyriaki" sort="Stamatelou, Kyriaki" uniqKey="Stamatelou K" first="Kyriaki" last="Stamatelou">Kyriaki Stamatelou</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Manamley, Nick" sort="Manamley, Nick" uniqKey="Manamley N" first="Nick" last="Manamley">Nick Manamley</name></noRegion><name sortKey="Addison, Janet" sort="Addison, Janet" uniqKey="Addison J" first="Janet" last="Addison">Janet Addison</name></country><country name="Suisse"><noRegion><name sortKey="Farouk, Mourad" sort="Farouk, Mourad" uniqKey="Farouk M" first="Mourad" last="Farouk">Mourad Farouk</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000225 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000225 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4245491
|texte= Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25367412" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a OpenAccessBelV2
| This area was generated with Dilib version V0.6.25. |  |